We work with the medical community to transform the lives of patients through the best scientific, management and leadership talent worldwide.
OTC drug makers, private research institutes, device manufacturers and others across the life science spectrum benefit from Boyden’s specialised expertise in meeting distinct talent needs.
Our discussion with Ray Pisani, President & CEO of Alberta Blue Cross on leadership, motivation, and the value of diversity.
Our discussion with Dr. Catherine Zahn, President & CEO of Centre for Addiction and Mental Health, on career drivers, leadership, and the diversity challenges that continue to face us today.
Our discussion with Alayne Metrick – President, St. Michael’s Hospital Foundation on leadership, diversity, team drivers and advice to the next generation.
Continuing to execute on its new R&D strategy, GlaxoSmithKline has agreed to buy the rights to a next-generation cancer immunotherapy from Merck.
By merging with Celgene in a record $74 billion deal, Bristol-Meyers will create a formidable organization in the competitive immunotherapy space.
Boyden’s Trevor Pritchard and Steve Nilsen placed Amy Efantis as new President and Chief Executive Officer of the Plasma Therapeutics Association (PPTA).